Is the α/β Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials?
- 1 June 2007
- journal article
- review article
- Published by Elsevier in Clinical Oncology
- Vol. 19 (5) , 289-301
- https://doi.org/10.1016/j.clon.2007.02.007
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- In regard to Brenner et al., IJROBP 2002;52:6–13International Journal of Radiation Oncology*Biology*Physics, 2002
- The prospects for new treatments for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissueInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Is the α/β ratio for prostate cancer low?International Journal of Radiation Oncology*Biology*Physics, 2001
- A simple analytic derivation suggests that prostate cancer α/β ratio is lowInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Is α/β for prostate tumors really low?International Journal of Radiation Oncology*Biology*Physics, 2001
- Toward optimal external-beam fractionation for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Is the prostate α/β ratio of 1.5 from Brenner & Hall a modeling artifact?International Journal of Radiation Oncology*Biology*Physics, 2000
- In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling detailsInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Fractionation and protraction for radiotherapy of prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1999